Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AbbVie
Biotech
Avalo’s phase 2 win fuels AbbVie chase despite placebo headwind
The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival drug, but the biotech’s stock rose in premarket trading.
Nick Paul Taylor
May 6, 2026 6:00am
AbbVie dips into boiling RAS waters with $1.45B biobucks deal
Apr 28, 2026 10:01am
AbbVie inks $745M deal with China’s Haisco for two pain assets
Apr 13, 2026 9:48am
Alzheimer's-focused Korsana uses Cyclerion merger to go public
Apr 1, 2026 9:54am
FDA rejects Aldeyra eye disease candidate for 3rd time
Mar 17, 2026 11:12am
AbbVie ties $350M bet to almost 10% weight loss after 12 weeks
Mar 9, 2026 9:50am